Physician profile
Taylor Barger
NPI 1407696123
$663.61
in general payments reported to CMS, 2019-2025
12 companies · $99.47 in 2025
The $99.47 reported for 2025 was less than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $564 · 2025: $99.47.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $663.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $294.11 | 2024-2025 | |
| Ucb, INC. | $95.01 | 2024 | Rystiggo, Zilbrysq |
| Tg Therapeutics, INC. | $65.73 | 2024 | |
| Csl Behring | $57.55 | 2024 | Hizentra |
| Merz Pharmaceuticals, LLC | $25.63 | 2024 | Xeomin |
| Biogen, INC. | $20.40 | 2024 | Spinraza |
| Alexion Pharmaceuticals, INC. | $19.55 | 2024 | Ultomiris |
| Neurocrine Biosciences, INC. | $18.24 | 2024 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.00 | 2025 | Relistor |
| Teva Pharmaceuticals USA, INC. | $17.64 | 2024 | Austedo Xr |
| Tanabe Pharma America, INC. | $16.32 | 2024 | |
| Pfizer INC. | $15.43 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Taylor Barger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.